Gilead, IPA, Natco & The Bells of Harmony
The post examines the collaboration between Gilead, IPA, and Natco Pharma regarding the sofosbuvir patent in India. It analyses how voluntary licensing and innovative policies are improving access…
sofosbuvir
2 articles
‘Killead’s Patent Application Killed by the Indian Patent Office!
Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C…